Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
Open Access
- 1 January 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 14 (5), S1
- https://doi.org/10.1186/ar3909
Abstract
Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides and has led to reappreciation of B-lineage cells for anti-rheumatic treatment strategies. Moreover, blocking B-cell activating factor with belimumab, a drug that is licensed for treatment of active, seropositive systemic lupus erythematosus (SLE), represents an alternative, indirect anti-B-cell approach interfering with proper B-cell development. While these approaches apparently have no substantial impact on antibody-secreting plasma cells, challenges to improve the treatment of difficult-to-treat patients with SLE remain. In this context, anti-CD19 antibodies have the promise to directly target autoantibody-secreting plasmablasts and plasma cells as well as early B-cell differentiation stages not covered by anti-CD20 therapy. Currently known distinct expression profiles of CD19 by human plasma cell subsets, experiences with anti-CD19 therapies in malignant conditions as well as the rationale of targeting autoreactive plasma cells in patients with SLE are discussed in this review.Keywords
This publication has 135 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Sustained antibody responses depend on CD28 function in bone marrow–resident plasma cellsThe Journal of Experimental Medicine, 2011
- Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedsideCurrent Opinion in Rheumatology, 2011
- Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2009
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis & Rheumatism, 2009
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy, 2009
- B cells in HIV infection and diseaseNature Reviews Immunology, 2009
- A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLEClinical Immunology, 2008
- Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximabAnnals Of The Rheumatic Diseases, 2007
- Expansion of CD19hiCD21lo/neg B Cells in Common Variable Immunodeficiency (CVID) Patients with Autoimmune CytopeniaImmunobiology, 2002